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Abstract  
Background: It is not known whether symptoms cluster together after esophageal cancer 
surgery or whether such symptom clusters are associated with survival in these patients.  
Methods: Data from a prospective Swedish nationwide cohort study of surgically treated 
esophageal cancer patients recruited between 2001 and 2005 were used. General and 
esophageal cancer specific symptoms were assessed using the EORTC QLQ-C30 and the 
QLQ-OES18 6 months post surgery. Associations between symptom clusters and survival 
were analyzed using Cox proportional hazards models, providing hazard ratios (HR) with 
95% confidence intervals (CI), adjusted for other known prognostic factors.     
Results: Among 402 patients reporting symptoms 6 months following surgery, three symptom 
clusters were identified. The first symptom cluster (‘fatigue/pain’) was characterized by 
symptoms of pain, fatigue, insomnia and dyspnea and was present in 30% of patients. The 
second symptom cluster (‘reflux/cough’) was characterized by symptoms of dry mouth, 
problems with taste, coughing and reflux and was present in 27% of patients. The third 
symptom cluster (‘eating difficulties’) was characterized by appetite loss, dysphagia, eating 
difficulties and nausea/vomiting and was present in 28% of patients. Presence of the 
reflux/cough and eating difficulties symptom clusters were associated with a statistically 
significantly increased risk of mortality (adjusted HR 1.43, 95% CI 1.08 – 1.89 and, adjusted 
HR 1.41, 95% CI 1.06 – 1.87, respectively).  
Conclusion: Symptoms experienced by surgically treated esophageal cancer patients appear 
to cluster together, and the presence of these symptom clusters have strong prognostic value. 
 
Keywords: symptoms; clusters; health-related quality of life; prospective; mortality.  
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Introduction  
Esophageal cancer is an aggressive disease associated with an extremely poor prognosis. The 
overall 5-year survival rate is as low as 10% in Europe.1 Surgical resection is the most 
established potentially curative treatment.2  The prognosis is unfavorable even when the tumor 
is surgically removed, with a post-operative 5-year survival rate of 31%.3 The operation is 
more extensive than most other standard surgical procedures and is associated with a 
substantial negative impact on patients’ health-related quality of life (HRQOL), 4-6 with 
patients suffering persistent problems with physical function and specific symptoms even at 3 
years postoperatively.7, 8 Although the majority of patients have recovered in terms of 
HRQOL functions and symptoms, and report scores similar to those of the background 
population at 5 years, a substantial minority of long-term survivors appear to further 
deteriorate over time.9  
Cancer patients often experience multiple concurrent symptoms as a result of 
their disease and treatment, and these tend to cluster together in systematic ways. For 
example, symptoms of fatigue, insomnia and depression are often experienced 
simultaneously.10, 11 In the past decade, the interest in the impact of symptom clusters on 
patient outcomes has increased, and symptom clusters may have a negative impact on survival 
in advanced cancer.12, 13 Esophageal cancer patients experience numerous symptoms 
following surgical treatment and previous studies have evaluated the impact of individual 
HRQOL functions and symptoms on patient outcomes.  Several aspects have been identified 
as prognostic indicators for survival in this group of cancer patients. Better pre-treatment 
physical and role functioning as well as global quality of life (QOL) are associated with better 
survival.14 Other studies have demonstrated an association between poor pre-treatment 
appetite loss, 15-17 fatigue, 18-20 dyspnea, 20, 21 reflux18 and an increased mortality risk. 
Moreover, poor post-operative global QOL, physical function and social function, as well as 
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symptoms of fatigue, pain, dyspnea, appetite loss, dysphagia and esophageal pain have been 
shown to predict mortality independently of established prognostic factors.22  
Although studies indicate a prognostic role of individual HRQOL functions and 
symptoms, it is not known whether post-surgery symptoms cluster together in a particular 
manner, or what the implications are of the presence of any such symptom clusters on patient 
outcomes. Therefore, we aimed to establish whether the symptoms experienced by esophageal 
cancer patients 6 months following surgery cluster together, and whether the presence of such 
symptom clusters are predictive of survival. 
 
Methods 
Study design 
A Swedish nationwide, prospective cohort study of esophageal cancer patients was conducted 
between April 2, 2001 and December 31, 2005. All patients in Sweden diagnosed with 
esophageal or esophago-gastric junctional cancer, whom underwent curatively intended 
surgery during the study period, were eligible for inclusion. The cohort included 90% of all 
surgically treated patients in Sweden during this time-period. Patients were followed-up with 
measures of HRQOL 6 months post-surgery. Ethical approval was granted by the Regional 
Ethical Review Board in Stockholm, Sweden, and informed consent was obtained from all 
patients. 
Clinical data collection  
The prospective data collection has been described in full elsewhere.23, 24 In brief, data were 
collected via a nationwide network of hospital departments and physicians involved in the 
diagnostics and treatment of patients with esophageal or esophago-gastric junctional cancer in 
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Sweden, and registered in the Swedish Esophageal and Cardia Cancer (SECC) database. 
Based on a pre-defined study protocol, data on patient and tumor characteristics as well as 
information regarding hospital, surgical treatment and complications were collected 
prospectively through manual review of medical records. Information on mortality was 
obtained via linkage to the 100% complete Swedish Register of the Total Population.  
Measures 
Several socio-demographic and clinical characteristics were assessed in the study and 
categorized as follows; age (<60, 60-74, or ≥75 years), sex (male or female), tumor stage (0-I, 
II, or III-IV), tumor histology (squamous cell carcinoma or adenocarcinoma), operation type 
(esophageal resection, cardia resection, extended total gastrectomy, or total gastrectomy and 
esophageal resection), post-operative complications (0, 1, or >1) and co-morbidities (0 or ≥1). 
Information on these characteristics was gathered from medical records. Post-operative 
complications were pre-defined and included perioperative bleeding, leakage or perforation of 
the anastomosis, stricture of the anastomosis, wound infection needing treatment, wound 
rupture, gastric perforation, intra-abdominal or intrathoracic abscess, ileus, thoracic duct 
injury, re-intubation or need for prolonged mechanical ventilation, paresis of the recurrent 
laryngeal nerve, pneumonia, pulmonary thrombosis, and myocardial infarction. Co-morbidity 
included angina, heart failure, hypertension, diabetes, pulmonary disease, renal failure, liver 
failure and other cancer. 
To assess symptoms, two HRQOL questionnaires were used in the study. The 
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C3025 was 
used to assess symptoms common among cancer patients in general, while the esophageal-
specific module QLQ-OES1826 was used to measure symptoms common among esophageal 
cancer patients in particular. The QLQ-C30 incorporates five functional scales, one global 
	   6 
QOL scale, one item about financial difficulties, three symptom scales assessing pain, fatigue 
and nausea/vomiting, and five single items addressing symptoms of dyspnea, sleeping 
difficulties, appetite loss, constipation and, diarrhea. The EORTC QLQ-OES18 contains four 
symptom scales addressing symptoms of dysphagia, eating difficulties, reflux and esophageal 
pain, and six single items assessing trouble swallowing saliva, choking when swallowing, dry 
mouth, trouble with taste, coughing or talking. The three symptom scales and five single 
symptom items from the QLQ-C30 and all symptom scales and single items from the QLQ-
OES18 were included in the analyses. Responses to the functional scales, global QOL and the 
financial difficulties question were not included in the present analyses as the aim of the study 
was to cluster symptoms not functions. Items were scored on a four-point scale; (1) “not at 
all”, (2) “a little”, (3) “quite a bit”, and (4) “very much”, referring to symptoms experienced 
during the past week. For the purposes of the current analyses, symptoms were recoded as 
binary variables to represent “presence” (for a response of 3 or 4) or “absence” (for a response 
of 1 or 2) of symptoms. This cut-off was based on previous work and clinical experience, 
representing a level of symptoms which would likely be noticed by clinicians in practice.6, 27  
Statistical analyses 
The symptom clustering was performed in two steps. In the first step, symptoms were 
clustered using the principal component analysis (PCA) method. In order to address the 
sensitivity of the final clusters to selected clustering methods, hierarchical cluster analysis 
(HCA) method was also used to compare the final clusters in this first step.28, 29  These 
methods (PCA and HCA) group symptoms in clusters so that the symptoms are highly 
correlated within their own cluster and have very low correlations with symptoms in other 
clusters. The splitting criterion with maximum eigenvalue of 1 was used to select the final 
cluster solution from the PCA method. Moreover, for the HCA method, the lowest maximum 
1 − R2 ratio value for a variable was used as the measure of clustering fit and to select the 
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final cluster solution. Among 18 symptom scales and single items, 14 symptoms with at least 
15% prevalence in the sample were selected for clustering (including symptoms of pain, 
fatigue, nausea/vomiting, dyspnea, sleeping difficulties, appetite loss, diarrhea, dysphagia, 
eating difficulties, reflux, esophageal pain, dry mouth, trouble with taste, cough).30  In the 
second step, patients were assigned cluster membership  if they suffered from at least 50% of 
symptoms from within a symptom cluster (i.e. symptom cluster present).13 Hence a patient 
could belong to more than one cluster.  
Chi-square test was used to examine between cluster differences on baseline 
socio-demographic and clinical characteristics. Multivariable logistic regression analysis, 
providing adjusted odds ratios (OR) with 95% confidence intervals (CI), was used to assess 
the baseline socio-demographic and clinical characteristics of final clusters. The symptom 
clusters were analyzed in relation to survival by the Kaplan-Meier method. Statistical 
significance was tested at the 5% level by the log-rank test. A Cox proportional hazard model, 
providing adjusted hazard ratios (HR) with 95% confidence intervals (CI), was used to 
analyze the 5-year survival of final clusters, controlling for confounding by baseline socio-
demographic and clinical characteristics (using the categorizations of variables as described in 
the measures section above). Logistic regression model was used to assess the discriminative 
power of these clusters using the area under the ROC curve. Due to the potential overlapping 
cluster membership, interactions between clusters were also tested at the 5% level of 
significance using Wald Chi-square test. PROC VARCLUS (SAS 9.2, SAS Institute, Cary, 
NC, USA) was used for PCA and HCA (with centroid option) clustering methods and SAS 
9.2 was used for other data analyses. 
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Results 
Patient characteristics 
During the study period, 616 patients were included in the cohort. Of these, 110 (18%) 
patients died within 6 months of surgery. Therefore, 506 patients were eligible for the present 
study and of these, 402 (79%) patients responded to the 6-month follow-up symptom 
assessment. There were no statistically significant differences between responders and non-
responders on any of the baseline clinical or socio-demographic characteristics. Baseline 
characteristics of the participating patients are detailed in Table 1. Based on the total group 
(n=402), patients were predominantly male (81%) and aged between 60 and 74 years (58%). 
The majority of patients were diagnosed with adenocarcinoma of the esophagus (76%) of 
tumor stage III (41%), and had undergone esophageal resection (76%). At least one 
complication was recorded in 133 (33%) patients, and the majority of patients (59%) had one 
or more co-morbidity.  
Cluster solution and characteristics of symptom clusters 
The final cluster solutions from PCA and HCA were identical with the exception of the 
symptom diarrhea which formed a single symptom cluster when using the HCA method. All 
other symptoms clustered into identical clusters produced by both methods.  We therefore 
selected the three-cluster solution by using the PCA method.  
Baseline characteristics of the three symptom clusters are presented in Table 1. 
The first cluster was characterized by symptoms of pain (general and esophageal), fatigue, 
insomnia and dyspnea. This cluster was named the ‘fatigue/pain’ (FP) symptom cluster. 
Among the 402 patients who responded to the symptom assessment at 6 months post-surgery, 
this cluster was present (i.e. meeting criteria for cluster membership by reporting at least 50% 
of symptoms in the cluster) in 122 (30%) patients and absent in 280 (70%). The most 
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prevalent symptom in this cluster was fatigue (97%). Cluster 2 was characterized by 
symptoms of dry mouth, problems with taste, coughing and reflux. This cluster was named 
the ‘reflux/cough’ (RC) symptom cluster. This symptom cluster was present in 107 (27%) 
patients and absent in 295 (73%). The prevalence of each of the four symptoms within this 
cluster was approximately 60%. The third cluster was defined predominantly by symptoms 
related to eating, such as appetite loss, dysphagia, eating difficulties and nausea/vomiting, and 
was named the ‘eating difficulties’ (ED) symptom cluster. The ED cluster was present in 112 
(28%) patients and absent in 290 (72%). The most prevalent symptoms in this cluster were 
eating difficulties (95%) and appetite loss (84%). The composition of the symptom clusters is 
presented in Table 2.  
Univariable differences on baseline characteristics within the clusters were 
assessed with Chi-square analyses. Younger age, higher tumor stage, squamous-cell 
carcinoma and more complications were associated with presence of the FP symptom cluster 
(all at p<0.05). Squamous-cell carcinoma and more complications were associated with 
presence of the RC symptom cluster, whereas with a higher tumor stage and more 
complications were associated with presence of the ED symptom cluster (all at p<0.05). No 
other statistically significant univariable differences were observed within clusters. 
Subsequent multinomial logistic regression analysis, adjusting for all other baseline 
characteristics, showed that compared with squamous-cell carcinoma, patients with 
adenocarcinoma were less likely to be assigned cluster membership to the FP symptom cluster 
(adjusted OR 0.49, 95% CI 0.28 – 0.84) and the RC symptom cluster (adjusted OR 0.54, 95% 
CI 0.32 – 0.94). Compared with having >1 complication, patients with no complications were 
less likely to be assigned cluster membership to the FP symptom cluster (adjusted OR 0.42, 
95% CI 0.21 – 0.84) and the ED symptom cluster (adjusted OR 0.46, 95% CI 0.23 – 0.93).  
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Presence of symptom clusters and mortality  
Median survival times for the FP, RC and ED symptom clusters were 18.13, 21.16 and 21.17 
months, respectively. Of the 402 patients responding to the 6-month follow-up symptom 
assessment, 124 (31%) were alive at 5 years. Figure 1 shows the Kaplan-Meier estimates of 
survival, illustrating the significantly reduced 5-year survival estimates (shown in months) for 
the presence of symptom clusters (log-rank test, p<0.001). Cox proportional hazards modeling 
demonstrated that symptom cluster was a significant predictor of mortality (Table 3). 
Following adjustment for age, sex, tumor stage, tumor histology, operation type, post-
operative complications and co-morbidities, presence of the RC and ED symptom clusters 
were associated with a statistically significantly increased risk of mortality (HR 1.43, 95% CI 
1.08 – 1.89 and, HR 1.41, 95% CI 1.06 – 1.87, respectively). Moreover, area under the ROC 
curve was 0.79 which shows that the clusters discriminate well between 5-year survivors and 
non-survivors. As patients could be assigned membership to more than one cluster (31 
patients belonged to all three clusters, 65 to both the PF and ED clusters, 48 to both the RC 
and ED clusters, and 55 to both the FP and RC clusters), interactions between the symptom 
clusters were also tested by introducing product terms in the Cox model (by using Wald Chi-
square test at the 5% level of significance). No interactions emerged as statistically 
significant.  
 
Discussion  
Using PCA, three symptom clusters were identified based on 14 self-reported general and 
esophageal cancer specific symptoms six months following curatively intended surgery. The 
identified symptom clusters were named ‘fatigue/pain’, reflux/cough’ and ‘eating difficulties’ 
based on the composition of symptoms forming each cluster. The presence of symptom 
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clusters at six months following surgery were significant predictors of survival duration, with 
the RC and ED symptom clusters emerging as statistically significant predictors of 5-year 
mortality. Presence of these symptom clusters conferred an approximately 40% increased risk 
of mortality. Importantly, the multivariable adjusted survival analysis demonstrated that these 
associations existed over and above what could be explained by other known prognostic 
factors, suggesting an important independent prognostic role of self-reported symptom 
clusters six months following esophageal cancer surgery.   
Strengths of the study include the population-based design, the high 
participation rate and large sample size, the high quality of clinical data, the use of well-
validated questionnaires, and adjustment for other known prognostic factors. This is the first 
study to examine symptom clusters among surgically treated esophageal cancer patients. 
Nevertheless, interpretations of results must be made cautiously as statistically derived 
clusters can be affected by several methodological considerations, and clinical relevance can 
be difficult to determine. Symptom clusters may vary according to the assessment of 
symptoms, the prevalence of symptoms in the sample, sample size and composition.13 In 
addition, the symptoms reported by patients were recoded into binary variables to estimate the 
extent of the presence or absence of a symptom based on the proportion of patients 
responding “quite a bit” and “very much” (i.e. symptom present) versus “not at all” and “a 
little” (i.e. symptom absent) to the symptom items in the questionnaires. Categorizing 
symptoms as present or absent addresses only one dimension of symptom experience; that is, 
symptom frequency. However, this categorization describing the proportion of patients 
experiencing a symptom based on responses of “very much” or “quite a bit” to items on the 
EORTC QLQ-C30 was used previously in symptom clusters research among cancer 
patients.27  Further, it is difficult to determine whether the symptom clusters identified in this 
study are stable long-term clusters. However, the assessment of symptoms at six months 
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following surgery was based on previous research suggesting that by this point the acute 
postoperative phase has subsided, and HRQOL and symptom levels have generally returned 
to a preoperative baseline value in the majority of patients.8, 31 Nevertheless, it would be of 
value to test the cluster solution on data obtained at different time points.  
There are two conceptual approaches to symptom clusters research, one 
involving the identification of symptom clusters in patients, and the other the identification of 
different sub-groups of patients based on their similar symptom profiles.10 In line with the 
methodology of one previous study of symptom clusters in advanced cancer, we clustered 
symptoms reported at six months; subsequently, the symptom cluster was considered present 
if patients reported at least 50% of symptoms within the symptom cluster.13 It is important to 
note that the use of these arbitrary cut-offs to determine cluster membership may have 
affected the clusters. However, the clinical importance of the symptom clusters identified in 
the present study is supported by the finding of an association between the presence of 
symptom clusters among patients and survival duration, independent of other prognostic 
factors.  
Although symptom clusters have not been assessed previously in this group of 
patients, findings from previous prognostic studies of individual symptoms and functions 
resonate well with the results of the present study. We identified a cluster characterized 
largely by symptoms related to aspects of eating (the ED symptom cluster). Both pre- and 
post-treatment appetite loss15-17, 22  and dysphagia22 have previously been identified as 
independent predictors of increased mortality among surgically treated esophageal cancer 
patients. Similarly, reflux has been shown to predict mortality among these patients.18 We 
also found that presence of the RC symptom cluster, characterized by reflux, dry mouth, 
problems with taste, and coughing, significantly predicted mortality. We identified a cluster 
largely composed of symptoms related to pain and fatigue (the FP symptom cluster) that was 
	   13 
associated with an increased risk of mortality (HR 1.2, CI 0.9-1.6). Although this association 
was not statistically significant, this is in line with previous studies which have found that the 
individual symptoms of pain and fatigue predict survival independently of a range of known 
prognostic factors among these patients (HRs ranging from 1.10 to 1.65).18-20;22   
Due to the poor post-operative prognosis for esophageal cancer patients 3, it is of 
utmost importance to further the understanding of factors related to prognosis. Previous 
research on the prognostic impact of symptoms has focused largely on the adverse impact on 
outcomes of individual symptoms. However, symptoms seldom occur in isolation, and this is 
the first study to date evaluating the prognostic role of symptom clusters in this patient 
population. Results from this study have potentially important implications for clinical 
practice. From a clinical perspective, targeting the symptoms in the ED and RC symptom 
clusters may be particularly important. It has been suggested that the most prevalent symptom 
within a symptom cluster may be an indicator for the presence of that particular symptom 
cluster. Thus targeting the most prevalent symptom in a symptom cluster may contribute to 
the streamlined assessment and management of symptoms to improve outcomes.32, 33 Should 
these results be confirmed in other studies, the findings may be used in clinical practice to 
direct additional investigations and symptom management strategies in patients who have 
undergone surgery for esophageal cancer.  
In conclusion, symptoms experienced by surgically treated esophageal cancer 
patients at six months post surgery appear to cluster together, and these clusters have strong 
prognostic value. If confirmed in future studies, these findings may have clinical relevance for 
the prediction of prognosis and planning of the follow-up care of these patients after surgery.  
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Figure legends 
Figure 1.  
Five-year survival in months according to the symptom clusters identified (fatigue/pain (a), 
reflux/cough (b), eating difficulties (c)), presented as Kaplan-Meier curves for patients with 
presence versus absence of these symptom clusters at six months following surgery for 
esophageal cancer.  
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Table 1. Baseline socio-demographic and clinical characteristics for the total sample of surgically treated esophageal cancer 
patients reporting symptoms at six months and for the symptom clusters identified 
    Symptom clusters 
Characteristic, n (%)  
Total  
  
Fatigue/pain Reflux/cough 
 
Eating difficulties 
  
(n=402) 
 Present 
(n=122) 
Absent 
(n=280) 
Present 
(n=107) 
Absent 
(n=295) 
Present 
(n=112) 
Absent 
(n=290) 
Age          
<60  101 (25)  40 (33) 61 (22) 19 (18) 82 (28) 28 (25) 73 (25) 
60-74  232 (58)  60 (49) 172 (61) 71 (66) 161 (55) 64 (57) 168 (58) 
>74  69 (17)  22 (18) 47 (17) 17 (16) 52 (18) 20 (18) 49 (17) 
Sex          
Female  75 (19)  24 (20) 51 (18) 24 (22) 51 (17) 23 (21) 52 (18) 
Male  327 (81)  98 (80) 229 (82) 83 (78) 244 (83) 89 (79) 238 (82) 
Tumor stagea          
0-I  84 (21)  17 (14) 67 (24) 19 (18) 65 (22) 15 (13) 69 (24) 
II  120 (30)  32 (27) 88 (32) 31 (29) 89 (31) 29 (26) 91 (32) 
III  161 (41)  60 (50) 101 (36) 51 (48) 110 (38) 59 (53) 102 (36) 
IV  33 (8)  11 (9) 22 (8) 6 (6) 27 (9) 9 (8) 24 (8) 
Tumor histology          
Squamous cell carcinoma 98 (24)  42 (34) 56 (20) 38 (36) 60 (20) 34 (30) 64 (22) 
Adenocarcinoma  304 (76)  80 (66) 224 (80) 69 (64) 235 (80) 78 (70) 226 (78) 
Type of operationb          
Esophageal resection  302 (76)  96 (79) 206 (74) 87 (81) 215 (73) 89 (79) 213 (74) 
Cardia resection  17 (4)  3 (2) 14 (5) 2 (2) 15 (5) 1 (1) 16 (6) 
Extended total 
gastrectomy 
 41 (10)  11 (9) 30 (11) 10 (9) 31 (11) 12 (11) 29 (10) 
Total gastrectomy and 
esophageal resection   
40 (10)  12 (10) 28 (10) 8 (7) 32 (11) 10 (9) 30 (10 
Complications          
0  269 (67)  67 (55) 202 (72) 59 (55) 210 (71) 63 (56) 206 (71) 
1  89 (22)  35 (29) 54 (19) 32 (30) 57 (19) 31 (28) 58 (20) 
>1  44 (11)  29 (16) 24 (9) 16 (15) 28 (9) 18 (16) 26 (9) 
Co-morbidity          
0  164 (41)  45 (37) 119 (43) 42 (39) 122 (41) 44 (39) 120 (41) 
≥1  238 (59)  77 (63) 161 (57) 65 (61) 173 (59) 68 (61) 170 (59) 
n number,  aMissing n=4, bMissing n=2. 
